Company Overview
Haemonetics Corporation operates as a medical technology firm that provides a comprehensive suite of hospital technology solutions across the United States and internationally. The company's product portfolio centers on automated plasma collection systems, donor management software, and supporting software solutions such as NexSys PCS and PCS2, which streamline the plasma donation process. This business falls within the Healthcare sector and the Medical Devices industry, positioning the firm to capitalize on the global demand for blood components and specialized medical equipment. The organization employs 3,023 individuals, reflecting a significant operational scale within the specialized medical device manufacturing landscape. With a market capitalization of $2.74 billion and annual revenue of $1.32 billion, Haemonetics holds a substantial footprint in the healthcare technology market. These valuation and revenue figures indicate that the company is a large-cap entity with a robust revenue base, suggesting a well-established market position and the capacity to fund continued research and development or geographic expansion.
Financial Health
The company reported revenue of $1.32 billion over the trailing twelve months, generating net income of $175.44 million and EBITDA of $364.90 million. The substantial gap between the $1.32 billion revenue and the $175.44 million net income reveals a cost structure where operating expenses, including cost of goods sold and overhead, consume approximately 86.7% of top-line revenue. Despite the recent revenue contraction of 2.7% year-over-year, the company maintains strong free cash flow of $335.05 million, which provides significant financial flexibility to manage capital expenditures, service debt, or pursue strategic acquisitions without relying on external financing. The company demonstrates healthy profitability metrics with a gross margin of 60.2%, an operating margin of 21.0%, and a profit margin of 13.3%. These margin levels indicate efficient production processes and pricing power, as the gross margin significantly exceeds the profit margin, highlighting the impact of operating expenses on final profitability. On the balance sheet, Haemonetics holds $363.56 million in cash against total debt of $1.23 billion, resulting in a debt-to-equity ratio of 134.40, which suggests a leveraged capital structure rather than a conservative one. However, the current ratio of 1.75 indicates that the company possesses sufficient current assets to cover its short-term liabilities, ensuring adequate liquidity for day-to-day operations. Return on equity stands at 19.3% while return on assets is 6.4%, revealing that the company generates high returns relative to shareholder equity but generates returns on assets that are more modest, a common dynamic for capital-intensive industries.
Valuation Assessment
The stock carries a trailing P/E ratio of 16.14 and a forward P/E of 11.01, implying that the market expects earnings to grow significantly in the future to justify the lower forward multiple compared to the historical trailing average. The price-to-book ratio is 3.01, indicating that the market values the company at more than three times its book value, which suggests a premium pricing for its intangible assets, brand, or growth prospects relative to its net asset value. Alternative valuation metrics further contextualize the stock's price, with a price-to-sales ratio of 2.08 and an EV/EBITDA of 9.82, suggesting the company trades at a premium to sales compared to many peers but offers a reasonable multiple relative to its earnings before interest, taxes, depreciation, and amortization. Regarding trading range, the 52-week high is $87.32 and the 52-week low is $47.32, meaning the current share price sits below the annual peak but above the annual trough, reflecting recent volatility. The beta of 0.31 indicates that the stock exhibits low price volatility relative to the broader market, moving less than one-third as much as the market index in either direction during periods of general market movement.
Growth & Income
Year-over-year, the company experienced a revenue growth rate of -2.7% and an earnings growth rate of 28.4%, demonstrating that earnings are growing substantially faster than revenue, which often implies improved operational efficiency, cost management, or a shift in product mix toward higher-margin offerings. As a non-dividend payer, Haemonetics does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company retains all earnings to reinvest into growth initiatives, debt reduction, or share buybacks rather than paying out dividends. The disparity between the negative revenue growth and positive earnings growth highlights a decoupling of top-line expansion and bottom-line performance, suggesting that profitability is being driven by internal factors rather than sales volume increases. Overall, the growth and income profile is characterized by strong profitability expansion despite a slight contraction in sales, while the absence of dividends directs capital toward internal corporate strategies rather than shareholder cash distributions.